Where to Buy CJC-1295, GHRP-2: Vendor Comparison & Research Info

This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabled as a drug, food or cosmetic.

CJC-1295

GHRP-2 and CJC-1295 stimulate two separate receptors that naturally boost growth hormone (GH) release from the anterior pituitary. CJC-1295 binds to the growth hormone releasing hormone receptor (GHRH) while GHRP-2 binds to the growth hormone secretagogue receptor[1]. By stimulating two different receptors in two different biochemical pathways that have the same final result, these peptides can work together to boost GH release from the anterior pituitary to levels that could not achieved by either peptide alone.

Both GHRP-2 and CJC-1295 have been tested in a variety of animal models and have shown positive effects on muscle hypertrophy and hyperplasia, cardiac function, and the immune system[2]–[4]. Both peptides also decrease blood sugar levels and favor lean body mass over fat deposition[5]. In fact, both peptides are known to stimulate fat loss by boosting metabolism[6]. This reduction in adipose (fat) tissue has been linked to improved insulin resistance and improvement in cases of type 2 diabetes.

When combined in research studies, these peptides have cooperative effects in at least some of the pathways noted above.

About The Author

The above literature was researched, edited and organized by Dr. E. Logan, M.D. Dr. E. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.

Scientific Journal Author

Dr. Dominique Bridon holds a Master of Science, Chemical Engineering and Polymer Sciences from Ecole Nationale Supérieure de Chimie and a PhD in Organic Chemistry from the University of Paris XI, ICSN, Orsay, France with Nobel Laureate Sir Derek H. R. Barton as Research Advisor. He completed his Post-Doctoral Research at the University of California, Berkeley. He studied the potential of CJC-1295 as a long lasting GRF analog and also held various leadership positions involving peptide research and technologies at Ipsen, Conjuchem, Redcell, and Abbott Laboratories. Dr. Bridon has served as a Director for Enobia (acquired by Alexion) and Neuronax and as a member of the Scientific Advisory Board of Syntaxin (acquired by Ipsen) and Biosortia. He now brings 30 years of executive and scientific leadership experience to the Epivax Oncology team.

Dr. Dominique Bridon is being referenced as one of the leading scientists involved in the research and development of CJC-1295. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between  peptide Review Hub and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide. Dr. Dominique Bridon is listed in [7] under the referenced citations.